Lupin Ltd — Capital/Financing Update 2024

Sep 18, 2024

==> picture [79 x 93] intentionally omitted <==

September 18, 2024

National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

BSE Limited

P. J. Towers, Dalal Street, Mumbai Samachar Marg, Mumbai - 400 001

Symbol: LUPIN

Scrip Code: Equity - 500257

Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and ‘ ’ Disclosure Requirements) Regulations, 2015 ( Listing Regulations ).

Dear Sir/Madam,

We are pleased to enclose a Press Release as regards, the Company having entered into non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan Tablets in the Indian market.

The above may kindly be considered as disclosure pursuant to Regulation 30 of the Listing Regulations.

The same is for your information and dissemination.

Thanking you,

For LUPIN LIMITED

Amit Kumar Gupta

Digitally signed by Amit Kumar Gupta DN: c=IN, o=Personal, title=7875, pseudonym=d30e6db65d0a41f2b9a52198e78bf149, 2.5.4.20=b7e8678b2d6b381cb8f4761d9cbb4338253df2c8e93e8fcf768f8e8643 8a00a1, postalCode=400705, st=Maharashtra, serialNumber=de9bbd80d8994e4be9f0dd2399144eba7e782d70287df6aad19 94f0b522fa08a, cn=Amit Kumar Gupta Date: 2024.09.18 12:56:12 +05'30'

AMIT KUMAR GUPTA COMPANY SECRETARY & COMPLIANCE OFFICER (ACS -15754)

Encl: a/a.

LUPIN LIMITED

Registered Office: 3[rd] Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel: (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLC029442 www.lupin.com

www.lupin.com

==> picture [68 x 70] intentionally omitted <==

BSE: 500257 NSE: LUPIN

REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin Enters into a Non-Exclusive Patent Licensing Agreement with Takeda to Commercialize Vonoprazan, a Novel Gastrointestinal Drug in India

Mumbai, September 18, 2024 : Global pharma major Lupin Limited (Lupin) today announced that it has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited (Takeda), to commercialize Vonoprazan Tablets in the Indian market. The drug will be marketed under the brand name Lupin’s Lupivon® and will be available in two strengths - 10 mg and 20 mg.

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.

"We are very pleased to commercialize Vonoprazan, a novel treatment option for Acid Peptic Disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients,” said, Rajeev Sibal, President India Region Formulations, Lupin.

Acid Peptic Disorder (APD) which includes Gastroesophageal Reflux Disease (GERD) and Peptic Ulcer Disease (PUD), is a highly prevalent disorder in India[1] . While prevalence of GERD ranges from 5% to 28.5%[2] , PUD has prevalence in the range of ~ 8%[1] . Risk factors for GERD include old age, high body mass index (BMI), non-vegetarian diet, tea/coffee intake, smoking and alcohol consumption[3] .

About Vonoprazan

Vonoprazan is a novel potassium-competitive acid blocker (P-CAB). Unlike traditional acid suppressants like PPIs, Vonoprazan offers unique attributes like complete proton pump inhibition with the first dose, longer duration of action resulting in effective control of nocturnal acid breakthrough, and meal-independent dosing.[4]

In India, Vonoprazan is approved by the DCGI for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment.

About Lupin

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to

Page 1 of 2

REUTERS: LUPIN.BO BLOOMBERG: LPCIN

==> picture [68 x 70] intentionally omitted <==

BSE: 500257

NSE: LUPIN

improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions. To know more, visit www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries please contact –

Rajalakshmi Azariah

Vice President & Global Head – Corporate Communications, Lupin rajalakshmiazariah@lupin.com

References

1 - Clinical profiling of patients with Acid Peptic Disorders (APD) in India: a cross sectional survey of clinicians

2 https://link.springer.com/article/10.1007/s12664-020-01104-0

[3 ] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140167/

4 https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215151s000lbl.pdf

==> picture [490 x 38] intentionally omitted <==

Page 2 of 2